Abstract
BackgroundUpadacitinib (UPA) is an oral reversible Janus kinase inhibitor. In patients (pts) with RA, UPA 15 mg once daily (QD) demonstrated better clinical responses at 12 weeks (wks) vs adalimumab...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have